$QEDN 2s thin!

$QEDN approves 40% share reduction http://x.co/4o2Qm

RECENT GOOD NEWS! $QEDN

RECENT GOOD NEWS! $QEDN

$QEDN SET FOR TAKEOFF

AMMG mines precious metals, possible HUGE PR this week!

$ETEK set to break out this week, penny land and then some

FTCH ROCKET FUEL!!!

$AMBS Gerald E. Commissiong President & CEO
Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus Financial Decisions from Stanford University.

PHARMSTAR (PHAR) NEWS!!!..

PHAR....NEWS..BYE TO PINKS!!!....


PharmStar to Pursue SEC Fully-Reporting Status

WILSON, NC, Oct 31, 2011 (MARKETWIRE via COMTEX) -- PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") announced today that it has started the process of becoming a fully-reporting company under U.S. Securities and Exchange Commission (SEC) regulations, in preparation for listing its shares on the OTC Bulletin Board (OTCBB).
Fully-reporting SEC status will allow PharmStar to pursue a listing on NASDAQ's OTC Bulletin Board, a regulated quotation service that displays real-time quotes, last-sale prices, and market depth and volume information for over-the-counter securities.

"I am committed to continuing our policy of transparency and complete disclosure, and this process is therefore mandatory for us if we are to achieve our goals," stated PharmStar CEO Howard Phykitt. "I believe that a listing on the OTCBB will enhance investor interest and confidence, lower our cost of capital, and make our stock more attractive to institutional investors. As the Company continues to progress toward this listing we will update our shareholders accordingly. As a first step, we have identified our audit firm and have begun organizing our historical corporate operations and financial results. We will then prepare SEC filings in anticipation of transitioning to fully-reporting status and application to the OTCBB early next year."

The Company completed the initial step in the process of becoming fully-reporting by retaining the accounting firm of Labrozzi & Company, P.A. The firm will immediately initiate an audit of PharmStar Pharmaceuticals, Inc. and its operations.

The Company's major milestones include completing its audit (4-6 weeks), the filing of a Form 10 (9-12 weeks) and 15c211, and the probable filing of an S1 registration. The Company's management expects the total process to take approximately 4 to 6 months.

About PharmStar Pharmaceuticals, Inc. PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug development, manufacturing and marketing company and the innovator of the FDA-approved liquid pain reliever, Aquaprin(TM). In development since 1993 with over $3 million invested to-date, Aquaprin(TM) is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin(TM)'s unique, multiple patent-pending formulas are designed to dissolve nearly instantly in just 1.5 ounces or more of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.

PharmStar initially plans to sell Aquaprin(TM) directly to nursing homes, outpatient and health care clinics, emergency units of hospitals nationwide, as well as retail distribution in selected local markets and third-party websites to be announced. All package engineering, product stability; shelf life testing and quality control research has been completed. PharmStar's headquarters are located in Wilson, NC.

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact:
PharmStar Pharmaceuticals, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com

Investor Contact:
investors@pharmstarinc.com


SOURCE: PharmStar Pharmaceuticals, Inc.
CONTACT: mailto:info@pharmstarinc.com
www.pharmstarinc.com/
mailto:investors@pharmstarinc.com

Copyright 2011 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs

PHAR LATEST NEWS!!!>>>>


PharmStar Pharmaceuticals Names Dr. James Carlson to Its Board of Directors and as Chairman of the Medical Advisory Board

DR.JAMES CARLSON IN ACTION>>>

BRAV will show year over year revenue gains in over 1000% for Q4 and will have its first profitable quarter, dont miss this one. BRAV Q3 financials will be out on the 27th, and will show a 220-250% gain over Q2-its highest revenue generating quarter of 100K. Due to BRAV's google adword campaigning remarkable results, BRAV bought in over 100K in revenue only for the first 18 days of Oct, as reported in the latest press release. This is just incredible, do not miss this one.

Everything is updated at the ibox daily. You will find links to everything I just said.

PHAR agreemment for AQUAPRIN Distribution!!...

PharmStar Announces Initial Distribution Agreement for Aquaprin

WILSON, NC, Oct 20, 2011 (MARKETWIRE via COMTEX) -- PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") today announced that it has signed a commitment letter for a 3-year wholesale distribution agreement for its signature product line, Aquaprin.
Alert Medical Supply ("AMS"), a worldwide wholesale distributor located in Brooklyn, NY, has committed to order a total of $5 million of Aquaprin over a three-year period, beginning upon PharmStar's initial operations for the production of Aquaprin, which Pharmstar's management is planning for the third quarter of 2012. The agreement will require the Company to meet a minimum order requirement over the period of the contract before additional product can be made available to other distribution channels. AMS will look to expand its distribution agreement to include extension products that have been developed by the Company as they become available in the product supply channel.

AMS is also making a direct investment in PharmStar through its Preferred D offering to further the Company's goals of meeting its production deadlines.

PharmStar CEO Howard Phykitt stated, "Distribution is a key function in getting Aquaprin to retail shelves in a timely manner, as we all know. We continue to develop distribution agreements with companies that have experience in getting products to market and on time. Alert Medical meets that goal for us, and we expect this partnership to grow as our ability to produce more Aquaprin grows. Additionally, AMS is now a minority equity partner, and as such is incentivized to help streamline the distribution process."

AMS President Babatunde Kupoluyi stated, "It is exciting to be the first distributor of Aquaprin. I had the opportunity to test Aquaprin, and it is a great product. I made the commitment to the Company with my first order, and show my belief in the product by putting together an equity position as well. I look forward to assisting in getting this aspirin product to market."

About PharmStar Pharmaceuticals, Inc. PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug development, manufacturing and marketing company and the innovator of the FDA-approved liquid pain reliever, Aquaprin(TM). In development since 1993 with over $3 million invested to-date, Aquaprin(TM) is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin(TM)'s unique, multiple patent-pending formulas are designed to dissolve nearly instantly in just 1.5 ounces or more of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.

PharmStar initially plans to sell Aquaprin(TM) directly to nursing homes, outpatient and health care clinics, emergency units of hospitals nationwide, as well as retail distribution in selected local markets and third-party websites to be announced. All package engineering, product stability, shelf life testing and quality control research has been completed. PharmStar's headquarters are located in Wilson, NC.

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact:
PharmStar Pharmaceuticals, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com

Investor Contact:
investors@pharmstarinc.com


SOURCE: PharmStar Pharmaceuticals, Inc.
CONTACT: mailto:info@pharmstarinc.com
www.pharmstarinc.com/
mailto:investors@pharmstarinc.com

Copyright 2011 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Financial Services:Commercial and Investment Banking
Financial Services:Investment Services and Trading
Pharmaceuticals and Biotech:Drugs
Medical and Healthcare:Facilities and Providers
Pharmaceuticals and Biotech:Biotech
Financial Services:Venture Capital

Giant News..PHAR...

PharmStar Outstanding Common Stock Reduced by 50%

WILSON, NC, Oct 17, 2011 (MARKETWIRE via COMTEX) -- PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company") today announced that its management and Board of Directors have directed a "rollback" of certain large blocks of shares of PharmStar Pharmaceuticals common stock held by management. This "rollback" was effective as of today.
The "rollback" means that the Company's Chairman and CEO, Howard Phykitt, has canceled and returned 535 million shares of his total holdings of the common stock of PharmStar Pharmaceuticals to the Company's treasury. He has accepted a series of warrants as follows:

-- A 5 year warrant to purchase 15,000,000 shares at $0.05 per share
beginning immediately;
-- A 5 year warrant to purchase 15,000,000 shares at $0.10 per share upon
the closing of an initial round of financing, such financing planned
to be $5 million and targeted to close within 150 days;
-- A 5 year warrant to purchase 15,000,000 shares at $0.15 per share upon
the closing of a follow-on round of financing, such financing planned
to be $2 million and targeted to close within 6 months after the
initial round;
-- A 5 year warrant to purchase 15,000,000 shares at $0.20 per share upon
the commencement of the Company's operations and production of its
products.

Additionally, the Company's Board of Directors has approved the reduction of authorized shares of common stock from 1,001,184,352 to 650,000,000.
Prior to the rollback, there were 998,879,352 issued and outstanding shares of common stock of the Company. As a result of the rollback, there are now 435,000,000 issued and outstanding shares of common stock of the Company, plus 15,000,000 set aside for the initial warrants, plus 55,000,000 shares set aside for future financings. This means that every shareholder of the Company now owns a greater percentage of the Company by a factor of approximately 2. The reduction of the total outstanding shares of the Company implies a greater share value for the holdings of the non-majority shareholders.

PharmStar CEO Howard Phykitt commented, "I am committed to preserving shareholder confidence and value to our Company. I sincerely appreciate the many investors who believe in our products and what it is that we plan to achieve. In the interest of maintaining shareholder value and adhering to our promise of limiting the number of authorized shares of common stock, I am surrendering the majority of my holdings of stock back to the Company's treasury, which I trust will only serve to increase shareholder value."

The primary purpose of the rollback is to spur the completion of the Company's funding.

Mr. Phykitt stated, "We have been negotiating for about 45 days on the best way to complete our financing for our expected rollout of Aquaprin next year, and it became clear that the market would best support this if we decreased the amount of shares available. I was determined that this would not be done on the backs of those that have supported this company, so I convinced all of the original, large shareholders to retire a large percentage of shares -- including me." Mr. Phykitt continued, "I made a promise to all shareholders that this Company would raise the needed capital and execute its business plan without undue dilution of its shareholders.

A feature of the rollback plan will allow Mr. Phykitt to purchase up to 60 million shares over time through the warrant feature.

"The warrant structure highly incentivizes me to lead the Company to a share price above the $0.25 mark," Mr. Phykitt concluded.

About PharmStar Pharmaceuticals PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin(TM), an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin(TM) is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Wilson, NC. For more information, visit www.pharmstarinc.com.

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact:
PharmStar, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com

Investor Contact:
investors@pharmstarinc.com


SOURCE: PharmStar Pharmaceuticals, Inc.
CONTACT: mailto:info@pharmstarinc.com
www.pharmstarinc.com/
mailto:investors@pharmstarinc.com

Copyright 2011 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs

VKML looking promising! Radar it guys!

GSPT, Corporate Overview:
Golden Spirit Enterprises Ltd. is an environmentally, socially conscious Company specializing in green technologies which will assist in fighting global warming and the march to help mankind.

TADF!! I agree Brad. I got my position cheap, and everyone is going to be sittin back wishin they had too. Check these out too man. TADF,HFBG these guys have been hot and are ready to run. I have large positions in them also. Why settle for one runner when you can have three JMO. GOOD LUCK AND LETS MAKE SOME MONEY TOFS!!!!!

$URCO Anyone?

TOFS, Nadendla, I f I may say hurry and get in! This is moving up and will move up quick! Up 22.22% today!

GLTY

BRAD

thanks !i am watching it!

TOFS is ready to EXPLODE!

Float just 230M!
O/S just 499M!

Big merger news coming July 5, 2011!

PPS just .0011, I see .05 to .10 soon!

HURRY!

GLTY

BRAD

PHAR!PHAR! SHAKING NEWS!!


PharmStar Pharmaceuticals Files Patents for Advanced Aquaprin Compositions and Manufacturing Methodology

WILSON, NC, Jun 15, 2011 (MARKETWIRE via COMTEX) -- PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin(TM), today announced the completion of the research and development that has culminated in the filing of U.S. patents for Aquaprin formulations, compositions, and processing methodology.
PharmStar's Chief Executive Officer, Mr. Howard Phykitt, also stated that the Company has additional product line extensions in the final development stages.

"A soluble aspirin and acetaminophen, (the active ingredient in Tylenol(R)) combination has been formulated to equal the active ingredients in Excedrin(R) but with up to 10 times faster acting results and little to no gastric intolerance," stated Mr. Phykitt. "Both aspirin and acetaminophen are insoluble in water, but with PharmStar's technology, both ingredients are solubilized into a clear good tasting drink in less than 30 seconds."

About PharmStar Pharmaceuticals PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin(TM), an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin(TM) is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact:
PharmStar, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com
Investor Contact:
investors@pharmstarinc.com

PHAR MOOOVES!!

WSHE Through our partnership with E-Seven International Corp., as E-Debit Global's exclusive sales and marketing agency we have opened up a powerful income business opportunity in the development of our 2nd generation distribution network. This unique marketing relationship provides non-conventionally supplied "Guaranteed Industry Best Products and Services" at "Guaranteed Industry Best Pricing" with a very transparent and easy to understand compensation plan delivered to our expanding and growing network of Independent Distributors and Sales Representatives".

NEWS!!!PHAR GOING FAAR!!

PharmStar Pharmaceuticals Announces the Formation of Its Medical Advisory Board

WILSON, NC, Jun 07, 2011 (MARKETWIRE via COMTEX) -- PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") today announced that it has begun to form a Medical Advisory Board as part of its plan to roll out Aquaprin in 2012. This board will consist of up to 6 physicians that will advise the Company's Board of Directors in making its initial offering of Aquaprin and Intsa-Prin to the medical community, including hospitals, nursing homes, doctors offices, and emergency vehicles, such as police and ambulance services. This advisory board will also recommend and direct testing protocol for making the substantially improved claims over any other over the counter pain relievers.
Additionally, one member of the medical advisory board will be seated on the Board of Directors of the Company. That representative will represent the medical community in the Company's governing body.

CEO Howard Phykitt stated, "Now that the Company is moving forward with implementing its operational objectives, we believe that it is now time to start building its governance bodies and management staff so that we may timely meet the Company's goals. First and foremost, the Company will place enormous value on the guidance of those to whom the marketplace will look to for affirmation of our product. It is my considered opinion that by including the medical community early in our corporate development, we will not only gain valuable and credible minds to aid the Company with the medical fields acceptance and the distribution strategy, but we will also begin the process of educating the most crucial participants to the development of the Company's market -- the physicians and emergency services themselves. The marketplace will be looking to this group in general, but its patients will be looking to them directly. We have determined that the most reasonable course of action is also the most simple; allow those who have the greatest expertise in the application of medicine to not only confirm the value of our product, but also assist the Company in getting Aquaprin to a market that desperately needs an extremely fast acting soluble aspirin product."

When the members of the advisory board are fully appointed, the Company will name The Chairman of its Medical Advisory Board, who will also serve as the newest member of its Board of Directors.

About PharmStar Pharmaceuticals PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin(TM), an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin(TM) is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Wilson, NC. For more information, visit www.pharmstarinc.com.

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of federal securities laws, commonly identified by such terms as "believes," "will," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact:
PharmStar, Inc.
919-794-7000
Email Contact

nice !!!

PHAR taking on bayer!

will be dropping by here,nice board guys

Sportsquest, Inc./Fielding Eyewear introduces the Mossy Oak RX3 Shooting Glasses to the Fielding Line of Camouflage Specialty Eyewear

THOMASVILLE, Ga., May 10, 2011 (BUSINESS WIRE) -- Sportsquest, Inc. (Pink Sheets: SPQS)/Fielding Eyewear (www.FieldingEyewear.com):
Fielding Eyewear announced today the development of a line of Mossy Oak(R) Shooting Glasses that will be offered in both camo and non-camo styles. Jim Spangler, Fielding's VP of Product Development & Marketing, says: "While the full details can't be released yet, this new line of innovative shooting glasses will incorporate optical features not seen before in shooting eyewear...especially eyewear priced under $100. In addition to interchangeable lenses and RX capability, a number of other special features will make these shooting glasses the 'eyewear of choice' for outdoorsmen (and women) the world over. Hunting and target shooting sports is a multi-billion dollar world-wide industry that occurs both indoors and outdoors. We're excited to be able to offer unique eyewear solutions that provide both shooting and sun protection along with exceptional quality and value for the consumer."

Spangler says once production is complete, the full specifications of these exciting new shooting glasses will be released. He also added that the new line of Mossy Oak Shooters will be covered by Fielding's Unlimited Lifetime Warranty. In addition to the new eyewear products, Spangler said Fielding would also be adding the Mossy Oak(R) pattern to their Optiflage(TM) lineup of camouflage eyewear accessories. www.FieldingEyewear.com

Fielding announced last week a license agreement with Haas Outdoors (Mossy Oak(R)) to launch a line of high definition camouflage reading glasses using Mossy Oak's new BreakUp Infinity(TM) pattern.

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

SOURCE: Sportsquest, Inc.

CONTACT:
Sportsquest, Inc. Jeffrey Burns, 352-678-4307
Copyright Business Wire 2011
-0-
KEYWORD: United States
North America
Florida
Georgia
Washington
INDUSTRY KEYWORD: Hunting
Outdoors
General Sports
Retail
Communications
Fashion
Marketing
Specialty
Sports
SUBJECT CODE: Product/Service

RMDT has Updated the Pink Sheets .com with NEW # of low float! New Sales of UTE and Audit under way!

Check out the RMDT I-Hub board and get on board quick!

GLTY

BRAD

BYSD

Should be your next home run pick!

New Video Chart:

PRGJ Coiling up on light volume, next increase in volume could lead to a nice rally!!! Time to get this board activated again. Peoplez need to Recognize... Therez too many nice playz out there. UTRM, TTII, PRGJ, CSKH, ICPA and more. Too many for me to list. Lets wake up peeps!!!

PRGJ been on a slow steady increase in volume the past week. Seems like the bottom is behind us and the next surge in volume could bring massive profits!!! PRGJ is it ready??? I think soooo!!!

UTRM and CSKH Wow How About Them 2!!!!!

UTRM and CSKH getting some nice uptick action today, keep them on your RADARZ!!!!

PRGJ! FINRA confirmed 11.6M SHORT! LOAD UP...HARD BOUNCE AND RUN COMING!

http://tinyurl.com/PRGJ-short-update-1262011

All the links on the spreadsheet are direct to the REGSHO/FINRA website. This is what is reported to them!

PRGJ is the next one!!!

I like this one a lot! Picked up some Monday after a twitter alert! Keep your eye on EMXC there are a lot of rumors about another push to .008!

OUR NEW HOME RUN PLAY GSTP!!!!

CURRENT PRICE: .605

Gold Standard Mining Corp (GSTP) -Market Cap 122.65 m
http://www.goldstandardmining.com/

-Gold Standard’s mission is to become an over one million ounce per year producer of minerals from the vast resources of Russia.

-The Company is currently producing about 200 ounces of gold per day during the mining season from its alluvial operation.

-The Company’s total gold resources and reserves are estimated at about 6.24 million ounces.

Silver

675 tons = 23.81 million ounces

»» Value: $420 million

Copper

418,000 tons = 921.53 million pounds

»» Value: $2.94 billion

Platinum

3 tons = 105,000 ounces

»» Value: $157 million

Molybdenum

6,400 tons = 14.11 million pounds

»» Value: $169.3 million

Gold:

195 tons = 6.878 million ounces

»»Value: $9.5 BILLION

TOTAL VALUE of GSTP’S RESERVES:

$13.5 BILLION

-Major Customer
During 2009 and prior years, the main customer of the Company was Sberbank. Sberbank is the undisputed leader of the Russian banking industry, accounting for over a quarter of national banking assets. http://www.sbrf.ru/en/
-GSTP extend the mining season this year for at least an additional thirty days due to favorable weather. “Based upon preliminary calculations, this summer’s alluvial mining results should be the best in the Company’s history. We look forward to reporting the actual results shortly upon completion of the season.” See November 2, 2010 Press.

REVENUE NUMBERS:

-Profit before income tax
December 31, 2009
»»$20,076,000

December 31, 2008
»»$22,427,000

December 31, 2007
»»$19,660,000
MISCELLANEOUS INFORMATION AND VALUATION ESTIMATIONS:

-There are some analysts reports that have been done that suggest a possible $4.25 per share price target based on current status.

- Revenues for the nine months ended September 30, 2010 were $17,252,000 compared with $25,211,000 for the nine months ended September 30, 2009. The company attributes the decrease in revenues to management’s decision not to sell the majority of gold until the last quarter of 2010 due to increases in the price of gold.

-There is speculation that Gold Standard Mining beat revenue and production estimates for this year. This stock is highly undervalued at .60 a share and these prices could appreciate quickly when they announce 4th quarter earnings and guidance.

-If we take last year’s net profit of $10,393,000 and calculate EPS, then give it a multiplier of 10x, we will find that the stock is priced in about right at .60…HOWEVER, that PPS does NOT include calculating in the $13.5 Billion dollars in Gold and mineral reserves that GSTP has. Also with projections of near term revenue and production growth you would say this could justify a higher P/E. This stock has tremendous upside from here compared to down side risk in our opinion.
..Sorry, the comment form is closed at this time.

SKZW look at this study it and do your dd....we like it at .0035 and we love it now....based on the story and charts....but always do your own dd!!!!! SKZW

that's a huge pick. thanks

i hope people listened to us few days ago about MNDP we told you look at the chart this baby reached bottom at .0002 was a great entry point....plus todays company udpate and boom we are traded as high as .0008 thats 400% in gains since our call at www.steamingredhotpicks.com

NEWS OUT ON BLAP!!!!!!!!

http://ih.advfn.com/q.php?pid=nmona&article=46062989&symbol=BLAP

Blast Applications, Inc. (PINKSHEETS: BLAP), a developer of iPhone, Twitter, Android, Nokia, and Facebook applications, is pleased to provide shareholders with an update of the corporate operations for 2011.

Blast Applications, Inc. believes that having appointed key people to its advisory board, will provide the necessary experience to move the Company forward at an unprecedented pace in 2011.

Our focus for the year 2011 remains high with growth and revenue. We are adding a new technology team to be able to store our apps with worldwide carriers, after already being an approved developer for I-Phone, Android, and Nokia we are looking to achieve the same with all the other major mobile phone application stores. Our goal is to have a series of new apps generating thousands of dollars from advertisements as well as additional revenue from direct payment by consumers.

There are real possibilities of a reality show with a major broadcaster in 2011. We are pleased to announce that William Morris Endeavor Entertainment, the largest talent and literary agency in the world, (N.Y., L.A., NASHVILLE, MIAMI, UK) has expressed interest in representing Can Do Better as a TV project for both Domestic and International Distribution.

"The company will not increase authorized shares nor will there be any reverse splits necessary to achieve our goal for 2011, we plan to stay current and to post our financials in the timely matter requested. Having the right people, transparency, and good planning will build a company that we can all be proud of to serve our shareholders interest. To keep our investors up to date we will provide a consistent flow of news with the latest achievements," stated Dino Luzzi, CEO of Blast Applications.

About Blast Applications, Inc.

Blast Applications, Inc. is a premier creator and developer of applications for iPhone®, Twitter® Facebook® and Nokia, allowing users to have more fun, be productive and make social media sites easier to use and more intuitive than before. Blast Applications has a unique opportunity to monetize the web surfer's dedication to social media sites through direct advertising programs tied to the Company's tools, applications and websites. For more information please visit www.blastapplications.com.

Forward Looking Statements

This release contains "forward-looking statements" and information provided by Blast Applications, Inc., such as online, printed documents, publications or information available via Blast Applications, Inc's website. It may contain certain forward-looking statements that involve risks, uncertainties, assumptions and other factors, which, if they do not materialize or prove correct, could cause Blast Applications Inc.'s results to differ materially from historical results, or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "planned," "expects," "believes," "strategy," "opportunity," "anticipates," and similar words. These statements may also include plans, strategies and objectives of management for future operations; any statements regarding proposed new products, services or developments; any statements regarding future economic conditions or performance; statements of belief; and any statements of assumptions underlying any of the foregoing.

Contact:

Blast Applications, Inc.

www.blastapplications.com

investor@blastapplications.com

COUGAR and KDKN are scam promotions. Get out while you can.

SCFR Gaining steam!!

KDKN (.23) owns 63% OF Cougar (4.89)
There is a promotion of Cougar involved of course but can KDKN
double from here? Have a stop loss.

Nice!!!!!

Yes I know :)